Adoptive transfer of tumor-primed, in vitro-activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response.
about
Enhanced response of T cells from murine gammaherpesvirus 68-infected mice lacking the suppressor of T cell receptor signaling molecules Sts-1 and Sts-2Induction of Wnt-inducible signaling protein-1 correlates with invasive breast cancer oncogenesis and reduced type 1 cell-mediated cytotoxic immunity: a retrospective studyPilot study of sentinel-node-based adoptive immunotherapy in advanced colorectal cancer.Tumor-primed, in vitro-activated CD4+ effector T cells establish long-term memory without exogenous cytokine support or ongoing antigen exposureA CpG-loaded tumor cell vaccine induces antitumor CD4+ T cells that are effective in adoptive therapy for large and established tumors.Synergy between CD8 T cells and Th1 or Th2 polarised CD4 T cells for adoptive immunotherapy of brain tumoursTh cells promote CTL survival and memory via acquired pMHC-I and endogenous IL-2 and CD40L signaling and by modulating apoptosis-controlling pathways.Alkylating agent melphalan augments the efficacy of adoptive immunotherapy using tumor-specific CD4+ T cellsRapid Functional Decline of Activated and Memory Graft-versus-Host-Reactive T Cells Encountering Host Antigens in the Absence of Inflammation.T cells sensitized with breast tumor progenitor cell vaccine have therapeutic activity against spontaneous HER2/neu tumorsAn evolutionary perspective on anti-tumor immunityRestoration of Retarded Influenza Virus-specific Immunoglobulin Class Switch in Aged Mice.Potent tumor-specific protection ignited by adoptively transferred CD4+ T cellsAnti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brainRole of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies.Therapeutic immunity by adoptive tumor-primed CD4(+) T-cell transfer in combination with in vivo GITR ligation.Escalating regulation of 5T4-specific IFN-γ(+) CD4(+) T cells distinguishes colorectal cancer patients from healthy controls and provides a target for in vivo therapy.IL-4 suppresses very late antigen-4 expression which is required for therapeutic Th1 T-cell trafficking into tumors.Enhancing adoptive immunotherapy of cancer.Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens.Cytotoxic chemotherapy and CD4+ effector T cells: an emerging alliance for durable antitumor effects.Active Immunotherapy of Cancer.MHC-class I-restricted CD4 T cells: a nanomolar affinity TCR has improved anti-tumor efficacy in vivo compared to the micromolar wild-type TCR.Transfer of in vitro-expanded naïve T cells after lymphodepletion enhances antitumor immunity through the induction of polyclonal antitumor effector T cells.Getting by with a little help from the right CD4(+) T cells.Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma.Depletion of CD4 T cells enhances immunotherapy for neuroblastoma after syngeneic HSCT but compromises development of antitumor immune memory.Requirement of tumor-associated antigen-specific CD4+ T cells for an efficient dendritic cell vaccine in antitumor immunotherapy.
P2860
Q27318672-242C84A5-83C3-43E2-BD58-6A75A142E4CDQ28538654-4F138847-3D91-4299-9016-501EA26E8928Q33928210-720AAFB5-176C-4358-A2AE-8E0FFCABE041Q33993999-C09FF106-CC0C-474C-A571-063ECD6EB2F4Q34568823-249BFD1C-B78B-42E6-B68E-9FA68D7F2413Q34744875-0D0CC193-5869-462C-BC51-5DD2D3E1B0DFQ34778623-BD1B65A1-5ACB-47C1-B680-ED6C1FF9CB41Q35071850-566C9466-FD7A-438F-819A-0B4A51E788F1Q35864495-373F6120-E384-4F6C-B69E-1B204F9C9D85Q35949083-4AE605F7-227D-4D3C-B89C-25FA6B58C194Q36522859-879152F7-2153-42EC-96C0-8D61408D735DQ36966471-FA6D4F85-FEA3-441F-BEF0-20E3EABF97ACQ37000845-971B0813-D7AB-4DCC-845E-B6AA17B736A1Q37037932-2382EC92-B1E2-435A-B1E8-667A695A2E40Q37107843-E87D90BA-2C9D-4E17-94C2-7F234C969B83Q37317178-C84A25C4-27B5-4AEF-A47C-384BE5E54E6DQ37434041-0F9F6B7A-89F8-449E-AFC2-857EEB1463A9Q37485130-0E8D2DAB-7E51-49E0-A156-4F4F968A5B00Q37687429-B38AA2E8-CDAB-4427-AEC2-2D1F30A24B98Q37706835-5AD08709-6876-4E91-9412-1BEC4FE351B5Q37991701-1E280047-35A1-47CB-A041-B91B132FB784Q38635419-C7DD2ED7-F85E-431F-A6E6-50D931D1C8ACQ39290133-1F3764D6-81F0-4A8A-AC86-5A42467D6D34Q40074591-DC060B17-76A9-4F11-B74E-4321CFFDD0CBQ42023994-09BF92C8-E21A-42ED-810A-D28D3552D906Q42141982-517F39BF-5429-4880-80CD-A30E9E83EEF0Q43129396-E92526EE-4B12-46C9-83B1-4795DE5E20B9Q45889980-A6CCB256-6DCE-4823-B522-81017DCBBBF2
P2860
Adoptive transfer of tumor-primed, in vitro-activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Adoptive transfer of tumor-pri ...... ynergistic antitumor response.
@ast
Adoptive transfer of tumor-pri ...... ynergistic antitumor response.
@en
type
label
Adoptive transfer of tumor-pri ...... ynergistic antitumor response.
@ast
Adoptive transfer of tumor-pri ...... ynergistic antitumor response.
@en
prefLabel
Adoptive transfer of tumor-pri ...... ynergistic antitumor response.
@ast
Adoptive transfer of tumor-pri ...... ynergistic antitumor response.
@en
P2093
P2860
P1433
P1476
Adoptive transfer of tumor-pri ...... ynergistic antitumor response.
@en
P2093
Gregory E Plautz
Li-Xin Wang
Mary L Disis
P2860
P304
P356
10.1182/BLOOD-2006-09-045245
P407
P577
2007-02-06T00:00:00Z